Patient-Reported Outcomes Measuring an Individual's Overall Self-Rated Health After Long-Term Treatment With Bulevirtide 2 mg for Chronic Hepatitis Delta in the Phase 3 MYR301 Trial

Conference Reports for NATAP

EASL - European Association
for the Study of the Liver
May 7-10, 2025
Amsterdam the Netherlands


Patient-Reported Outcomes Measuring an Individual's Overall Self-Rated Health After Long-Term Treatment With Bulevirtide 2 mg for Chronic Hepatitis Delta in the Phase 3 MYR301 Trial

	EASL 2025 May 7-10 Amsterdam